Markets:

Overview

News

Currencies

International

Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

28.88 +1.47 (+5.36%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Quince Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

American Minerals (OTC: AMLM) Strategic Acquisition Expands Gold Assets in Western Australia as Metals Spike – More Stocks Inside

March 31, 2026

Via AB Newswire

Topics Artificial Intelligence Economy

Stocks Under $0.10: ITRM, AMLM, BFRG, QNCX, ADMQ March Madness Watch

March 30, 2026

Via AB Newswire

Topics Artificial Intelligence Economy

Quince Therapeutics Settles Approximately $16.4 Million of Debt

March 30, 2026

From Quince Therapeutics, Inc.

Via Business Wire

American Lithium Minerals (OTC: AMLM) Highlights Critical Catalyst Advancements, Multi-Commodity Growth and Upside Potential

March 23, 2026

Via AB Newswire

Topics Artificial Intelligence

Micro-Caps Under $1: TOON, PRSO, RENX, QNCX, KIDZ Building Momentum

February 11, 2026

Via AB Newswire

Topics Economy Intellectual Property

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

February 09, 2026

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

January 29, 2026

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

January 28, 2026

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

December 15, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

December 10, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Participate at Investor Events in December 2025

November 24, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

November 12, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

November 10, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

September 25, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

October 09, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

September 11, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 11, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

August 07, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

July 16, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

July 10, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference

June 25, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

June 18, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

June 12, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

June 03, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Present at Citizens Life Sciences Conference

April 30, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

April 03, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

March 24, 2025

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

February 07, 2025

From Quince Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.